This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Apr 2011

Lpath Launches Retinal Detachment Drug Trial

The Phase Ib/IIa trial will enrol 32 subjects with pigment epithelium detachment, who will receive up to three monthly intravitreal injections of iSONEP.

Lpath has initiated enrolment in patients with retinal pigment epithelium detachment for Phase Ib/IIa trial of iSONEP, the company's ocular drug candidate.

 

Pigment epithelium detachment is a potentially serious condition that is often part of the pathology of wet age-related macular degeneration and polypoidal choroidal vasculopathy; no drug has yet been approved to treat this condition.

 

The Phase Ib/IIa trial will enrol 32 subjects with pigment epithelium detachment, who will receive up to three monthly intravitreal injections of iSONEP. Two dose levels will be evaluated.

 

The primary endpoint of the study is the tolerability of consecutive monthly inj

Related News